NCT05613972 Integrated Suicide & Trauma Therapy for Suicide Risk
| NCT ID | NCT05613972 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Unity Health Toronto |
| Condition | Suicide |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-12-08 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-12-08 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators have developed a novel suicide intervention, Integrated Suicide and Trauma Therapy (ISTT). ISTT combines Brief-Skills for Safer Living (Brief-SfSL)-a promising method to enhance coping skills and reduce suicidality-with a trauma therapy component to alleviate the specific impacts of childhood trauma on suicide risk. The aim of this pilot is to test 12-weeks of ISTT to alleviate suicide risk among individuals with a history of childhood trauma and current suicidality.
Eligibility Criteria
Inclusion Criteria: * Beck Scale for Suicidal Ideation \> 10 * Presence of childhood trauma defined by a minimum moderate score on any of the Childhood Trauma Questionnaire subscales (emotional abuse, physical, abuse, sexual abuse, emotional neglect, and physical neglect * Presence of any psychiatric diagnosis * Ability to provide informed consent * Not receiving other psychotherapy concurrently * Ability to undergo psychotherapy in English Exclusion Criteria: * The presence of cognitive impairment that would limit consent or understanding of ISTT * The presence of active psychosis * Unwilling or unable to provide informed consent
Contact & Investigator
Sakina Rizvi, PhD,MACP,RP
PRINCIPAL INVESTIGATOR
Unity Health Toronto
Frequently Asked Questions
Who can join the NCT05613972 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05613972 currently recruiting?
Yes, NCT05613972 is actively recruiting participants. Contact the research team at rizvisa@smh.ca for enrollment information.
Where is the NCT05613972 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT05613972 clinical trial?
NCT05613972 is sponsored by Unity Health Toronto. The principal investigator is Sakina Rizvi, PhD,MACP,RP at Unity Health Toronto. The trial plans to enroll 20 participants.